News

BioM's articles and press releases about the Bavarian biotechnology sector


Gateway to Asia

Aus­trali­en trade com­mis­sion of­fers busi­ness lunch with a focus on neur­os­cience

Bavarian biotechnology visits Japan

16 Bav­ari­an bi­otech com­pan­ies are par­ti­cip­at­ing in the trade mis­sion

4SC announces compelling data for anti-cancer agent Resminostat

Res­ults of the phase II study of Soraf­en­ib/Re­sminostat com­bin­a­tion ther­apy in ad­vanced liver can­cer

High expectations at MorphoSys

Two stud­ies un­der­line the im­port­ance of tar­get mo­lecule of the drug can­did­ate against rheum­at­oid arth­rit­is

Impressive pipeline for personalized medicine

Roche presents its de­vel­op­ment pipeline and com­mits it­self to Per­son­al­ized Medi­cine

MorphoSys attracts investors from the US

After Mark Lampert now also Mor­gan Stan­ley in­vests in Mu­nich's bi­otech local hero

Investors trust WILEX

Com­bined cap­it­al in­crease suc­cess­fully com­pleted totalling EUR 23.9 mil­lion

Registration is opened

Pre­lim­in­ary pro­gramme of the 2nd Mu­nich Bio­mark­er Con­fer­ence, Novem­ber 22nd-23rd

Japanese health care and pharma industry

Op­por­tun­it­ies for Ger­man life sci­ence SMEs

MorphoSys Antibody Reaches Major Milestone in Collaboration with Roche

Alzheimer Antibody Gantener­u­mab Clin­ic­al Trial Ex­pan­ded to Pivotal Phase 2/3 Study

Newsletter

Subscribe

Archive



Publish press release

 To the login


Gabriele Klingner
Gabriele Klingner

Communications & Marketing Lead


Christiane Proll
Christiane Proll

PR & Social Media Manager